J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p1,580.00. The ...

Mr Rajarshi (Rishi) Mukherjee, a Ronald Finn Senior Research Fellow has become the first recipient of the prestigious Medical ...

DelveInsight’s Advanced Cervical Cancer pipeline report depicts a robust space with 70+ active players working to develop 75+ ...

Dr. Blackman brings his singular experience as co-founder of Day One Biopharmaceuticals and a physician-scientist in pediatric neuro-oncology to the PBTF’s pediatric brain tumor communityBOSTON, Jan.

The Marketing Association of Pakistan (MAP) has announced its newly elected office bearers and Council members. Muhammad ...

Zentalis Pharmaceuticals, Inc.’s ZNTL share price has dipped by 21.25%, which has investors questioning if this is right time ...

Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

World’s First “Universal” Robotics Software Platform BOW Raises £4 Million Seed to Reduce Cost and Complexity of Programming ...

Learn more about whether Ionis Pharmaceuticals, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Tempus AI is projected to achieve 30% YoY top line growth in Q4 2024 as presented in its preliminary results. Click here to ...